Aerosol salbutamol administration by IPPB: lowest effective dose

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Asthma management often involves bronchodilators like salbutamol.
• Intermittent positive-pressure breathing (IPPB) is a method for delivering inhaled medications.

Purpose of the Study:

• To evaluate the efficacy of low-dose aerosolized salbutamol administered via IPPB compared to standard doses.
• To assess the bronchodilator effect and duration of action of varying salbutamol doses.

Main Methods:

• A randomized study involving asthmatic subjects assessing FEV1 (forced expiratory volume in 1 second).
• Radiotracer technique used in normal subjects to measure aerosol deposition during IPPB.
• Comparison of 1.0 mg, 2.5 mg, and 5.0 mg doses of salbutamol.

Main Results:

• No significant difference in peak bronchodilator effect (FEV1) between 1.0, 2.5, and 5.0 mg salbutamol doses.
• The 5.0 mg dose resulted in a significantly longer duration of effect but also more adverse effects.
• Aerosol deposition in the lungs showed an inverse relationship with tidal volume during IPPB, with a maximum deposition of approximately 10%.

Conclusions:

• Lower doses of salbutamol delivered by IPPB can achieve comparable peak bronchodilation to higher doses.
• Dose selection for IPPB should consider the balance between efficacy, duration, and potential for adverse effects.
• Understanding aerosol deposition patterns during IPPB is crucial for optimizing drug delivery in respiratory conditions.